Xeris Biopharma Holdings (XERS) Intangibles (2021 - 2026)

Xeris Biopharma Holdings has reported Intangibles for 6 years, with the latest figure at $85.4 million in Q1 2026.

• For the quarter ending Q1 2026, Intangibles fell 11.27% year-over-year to $85.4 million; the trailing twelve-month figure through Mar 2026 stood at $85.4 million (down 11.27% YoY), and the FY2025 full-year result was $88.1 million, down 10.96% from the prior year.
• Intangibles for Q1 2026 stood at $85.4 million, down from $88.1 million in the prior quarter.
• The five-year high for Intangibles was $128.7 million in Q1 2022, with the low at $85.4 million in Q1 2026.
• Historically, Intangibles has averaged $107.1 million across 5 years, with a median of $107.1 million in 2024.
• Annual changes were most pronounced in 2022 — Intangibles retreated 8.25% — and 2026, when it slipped 11.27%.
• Xeris Biopharma Holdings' Intangibles stood at $120.6 million in 2022, then declined by 8.99% to $109.8 million in 2023, then decreased by 9.88% to $98.9 million in 2024, then decreased by 10.96% to $88.1 million in 2025, then slipped by 3.08% to $85.4 million in 2026.
• The last three Intangibles figures came in at $85.4 million (Q1 2026), $88.1 million (Q4 2025), and $90.8 million (Q3 2025), per Business Quant data.